Aradigm Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
9,717.00
33,561.00
23,429.00
195.00
14,465.00
SG&A Expense
13,289.00
37,088.00
40,367.00
30,094.00
21,289.00
EBIT
3,942.00
3,837.00
17,141.00
30,020.00
6,942.00
Unusual Expense
15,970.00
8,845.00
11.00
384.00
-
Non Operating Income/Expense
9.00
85.00
86.00
984.00
15.00
Interest Expense
1,649.00
288.00
-
2,406.00
3,870.00
Pretax Income
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
Consolidated Net Income
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
Net Income
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
Net Income After Extraordinaries
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
Net Income Available to Common
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
EPS (Basic)
2.36
0.32
1.17
2.23
0.72
Basic Shares Outstanding
9,154.10
14,700.00
14,747.00
14,779.00
14,860.00
EPS (Diluted)
2.36
0.32
1.17
2.23
0.72
Diluted Shares Outstanding
9,154.10
14,726.00
14,747.00
14,779.00
14,860.00
EBITDA
3,572.00
3,527.00
16,938.00
29,899.00
6,824.00
Non-Operating Interest Income
6.00
17.00
29.00
88.00
92.00

About Aradigm

View Profile
Address
3929 Point Eden Way
Hayward California 94545
United States
Employees -
Website http://www.aradigm.com
Updated 09/14/2018
Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its technologies include diabetes and pain management, AERx essence devices. The company was founded in 1991 and is headquartered in Hayward, CA.